Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:41:48.157Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:41:48.157Z.
Quote observation: 2026-10-06T16:34:57.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ae4e4394aaeb0d5c8b7c6b49623c27b4c6984d6a5511a37bd4b8ffeab1df45fa
FORWARD PE RATIO
N/A
Curanex Pharmaceuticals Inc Common Stock
Market Cap
$6.94M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Curanex Pharmaceuticals Inc Common Stock (CURX) | $6.94M | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.98M | N/A |
| Mangoceuticals, Inc. (MGRX)vs › | $7.00M | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.78M | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.76M | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.16M | N/A |
| Aclarion, Inc. (ACON)vs › | $6.69M | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.25M | N/A |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.62M | N/A |
| Longeveron Inc. (LGVN)vs › | $7.27M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
